AstraZeneca bets on Ivonescimab: Summit Therapeutics rises 18% in after-hours trading
Reading Time: 3 minutes
AstraZeneca invests $2 billion in Summit Therapeutics, causing the stock to rise approximately 18% in after-hours trading. At the center is Ivonescimab. The antibody has delivered strong Phase III data and is now set to be combined with AstraZeneca's cancer medications. The FDA is expected to decide on the first US approval on November 14. Summit is preparing for the commercial launch. Summit Therapeutics (SMMT) is a biopharmaceutical company focused on cancer drugs. The spotlight is on Ivonescimab, a bispecific antibody that blocks both...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
